We evaluated the Kodak Ektachem DT system (DT6O, DTE, DTSC modules), using it as a mobile laboratory unit (MLU) in different hospital settings. Imprecision of 19 assays performed with the system and correlation with routine methods in the main laboratory were assessed. The system was then transported to different departments within the hospital, where limited test profiles were offered and the time taken to produce results was recorded. It proved practicable to offer a six-test electrolyte profile to a five-bed intensive-care unit but not to an 18-bed renal unit, where more selective analysis would be required. In a low-throughput outpatient clinic (five patients per hour) it was feasible to provide a six-test on-site profile on every patient, whereas the maximum number of tests was four in a high-throughput clinic (10 patients per hour). The cost of providing a flexible extra-laboratory biochemistry service must be balanced against the benefit of having on-site results, e.g., fewer outpatient-clinic visits.
system in different hospital settings (an intensive-care unit, a renal unit, and outpatient departments)
as an expansion of such extra-laboratory services. Several aspects of this system were explored, including mobility, timing of analytical proffles, and tailoring proffles to the needs of particular clinical units.
Methods
The Ektachem DT System was kindly provided by the manufacturers (Kodak Ltd., Hemel Hempstead, U.K.). All modules use disposable multilayer reagent slides originally designed for larger clinical analyzers (2) . The main module, the DT6O, contains the controlling microcomputer and a reflectance photometer for colorimetry.
The DTE module is designed for potentiometry, and the slides used in it are constructed as mini ion-selective electrodes (3). The DTSC module contains a separate reflectance photometer and is used for kinetic enzymatic analyses (4) .
We assessedthe performance of 19 of the 22 tests currently available on the DT system, omitting only tests for ammonia, hemoglobin, and lactate dehydrogenase. Withinrun imprecision was measured by repeated analyses of pooled patients' serum. Between-run imprecision was assessedwith commercially available quality-control material (Precipath U; Boehringer Corp., London, U.K.) The performance of the DT system was compared with that of standard Department of Pathological Biochemistry, Western Infirmary, GlasgowGil 6NT, Scotland,U.K.
'Address correspondenceto this author. Time taken to perform each analytical proffle was divided into sample-handling time (centrifugation and pipetting of sample) and analytical time (time for the instrument to provide complete proffle results).
Quality-control material (Gilford QCS; Ciba Corning, Halstead, U.K.) was assayed at the beginning of each session for each assay that was to be used. We also participated in the Internal Quality Assurance Scheme within the laboratory as well as U.K. National External Quality Assurance Schemes.
The system was recalibrated once every six to eight weeks. The manufacturers recommend recalibration at least once every three months.
The system was operated by laboratory personnel throughout the study. Training of new personnel comprised a half day of instruction on the operation of the system within the laboratory followed by one supervised session outside the laboratory. Results were entered onto preprinted forms, which could be filed into the case notes, as well as onto worksheets, which were filed in the laboratory.
Results

Imprecision. Our findings for within-run
and between-run imprecision were consistent with the work of others (4-10). Full details are available from us.
Comparison with routine methods. From the 19 Ektachem assays investigated, we could categorize three groups of analytes, according to the correlation with the methods currently in use (Table 1) .
In Group 1, least-squares regression lines had slopes between 0.91 and 1.23 for 12 assays.
In Group 2, the five enzyme tests showed considerable differences in slope as compared with existing methods (0.29 In Group 3, the two tests (sodiumand TCO2) had regression slopesof 0.75 and 0.79, respectively. We improved these toward unity by using Deming regression statistics (11).
Group
Mobile laboratory unit timing analysis. At each location there was an obligatory instrument warm-up time (DTh0 module =20 mm, DISC =5 mm, and DTE <1 mm). Times required to produce patients' results, including possible repeat dilutions, are shown in Table 2 .
Mobile laboratory unit in the intensive-care unit. The electrolyte profile was further tested by longitudinal monitoring of three patients in the intensive-care unit for as long as seven days (Figure 1) . The best agreements between Ektachem and routine methods were achieved for potassium and urea (average biases for urea in patients 1, 2, and 3 were + 1.0, +0.9, and -0.1 mmolJL, and for potassium they were +0.1, -0.2, and 0 mmol/L, respectively).
For creatinine analysis there was a consistently negative bias (-15, -31, and -31% for patients 1, 2, and 3, respectively) . Sodium analysis was characterized by a variable bias in the patients studied, particularly patient 3. TCO2 and chloride also showed variable bias, even within individual patients. Figure 2 shows the procedure for the use of the mobile laboratory unit in the outpatient clinic.
Mobile laboratory unit in the lipid clinic.
Discussion
We tested the performance of the Ektachem DT system, assessing 19 of the 22 assays available. Previous evaluations dealt with the individual DT modules-DT6O
(5-7), DTSC (4)-or DT6O/DTE (8, 9). The only evaluation of the complete DT system was by Landaas and Juell (10), who tested only 11 assays. Our imprecision data support the results of others, confirming the reliable analytical performance of the system. On-site analysis in a hospital setting requires that the results obtained be fully compatible with those from the central laboratory. Our assessment of the DT system demonstrated that the 12 Group-i assays could be integrated into the hospital laboratory system without any modifications.
The five enzyme assays (designated as Group 2) had slope differences that were methodological in origin. Integration of these particular assays into the routine service might require adjustment of instrument settings on the Ektachem for its results to mimic those of existing methods, or the establishment of new reference intervals for these Ektachem assays.
Regression slopes and intercepts were improved by using Deming regression statistics for the Group-3 assays, sodium and TCO2. Again, methodological differences exist, e.g., direct ion-selective-electrode measurements for sodium in the Ektachem DTE module compared with indirect ionselective-electrode measurements from the Technicon src.
However, bias between the results was not consistent, even day-to-day for the same patient. Integration of these tests should be considered with care, particularly if the Ektachem results are to be used in parallel with the existing clinical chemistry service.
The system was easy to relocate within the hospital. However, the 20-nun obligatory warm-up time proved to be a disadvantage.
The aim of the six-testproffle offered in the inpatient areas of the renal unit and intensive-care unit was to provide comprehensive information concerning the patients' electrolyte status, including that needed for calculation of the anion gap. A full proffle took 15 mm, plus an 10 mm for urea-sample dilution if the value exceeded 30 mmol/L (12). This timing was acceptable in a five-bed intensive-care unit where urgent measurements on only one or two patients might be required at any one time, but proved not to be feasible for regular monitoring of patients in a busy renal unit. At present, therefore, a full electrolyte profile could reasonably be requested only on selected patients in such units, although a limited proffle (e.g., potassium and creatinine) would be possible for all patients.
In outpatient clinics the feasibility of multitest proffling was found to depend on patient throughput. In a busy diabetic clinic, as many as four test results could be provided for each patient, whereas in a low-throughput lipid clinic a six-test proffle was possible. The full six-test proffle was performed on new patients attending the clinic, not only to allow assessment of total cholesterol and triglycerides but also to screen for some of the secondary causes of hyperlipidemma.Follow-up patients at the clinic had only total cholesterol and triglycerides measured.
Our system was operated by laboratory personnel. Training and familiarization could be completed in just haifa day. However, it is well established that the performance of any such system can be diminished when it is operated by nonlaboratory personnel or when it is used infrequently (13).
The introduction of bedside testing in a hospital may result in a decrease in the laboratory workload per Se, while at the same time leading to an increase in the workload of junior medical and nursing staff. A study by Geaiy and O'Leary (8) showed that when the DT6O was left for sideroom testing in a hospital, as a substitute for the routine emergency service, only 17% of the medical staff who had been trained to use it performed one or more tests.
It is important that quality-control materials be regularly assayed and the results recorded. The quality of results should be compatible with those from the main laboratory. Even if the main operators of on-site analyzers are nonlaboratory personnel, the laboratory should have a role in maintenance and collation of quality-control data.
The provision of an on-site analytical service would appear at face value to be expensive. The current capital cost in the U.K. of the complete DT system is $16 380, with individual reagent slides ranging from $0.80 to $1.50. At a single session (e.g., lipid clinic), calibration and qualitycontrol materials and extra reagent slides cost, on average, $23. Thus the clinical benefits of an on-site service should be weighed against the increased cost. Availability of on-site results in an outpatient clinic allows a more meaningful consultation between patient and clinician and may reduce the number of return visits to a clinic. More studies are required to quantifr and cost-evaluate any advantage and balance this against the increased cost of the service.
In our view, introduction of the mobile laboratory unit could provide a high-quality, flexible, on-site service for use in intensive-care areas as well as in outpatient clinics as an extension of the clinical chemistry laboratory service.
